About Contact Us Careers

Growth Hormone Deficiency Market - Top Companies and Manufacturers

Request Free Sample Copy

Report ID: 2683
Published Date: Oct 16, 2024
Report Format: PDF, PPT

Buy Now

Companies Dominating the Growth Hormone Deficiency Landscape

Merck KGaA
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Teva Pharmaceuticals Industries Ltd.
Ipsen Pharma Biotech SAS
Novartis AG
Pfizer, Inc.
F. Hoffmann-La Roche Ltd
Ferring B.V.
Novo Nordisk A/S
Eli Lilly and Company
AnkeBio Co., Ltd

Browse Key Market Insights with Data Illustration:

Growth Hormone Deficiency Market Size & Share, Growth Trends 2036

In the News

Author Credits: Radhika Pawar

Report ID: 2683
Published Date: Oct 16, 2024
Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of growth hormone deficiency is assessed at USD 4.64 billion.

Growth Hormone Deficiency Market size was valued at USD 4.51 billion in 2023 and is expected to reach USD 7.23 billion by 2036, registering around 3.7% CAGR during the forecast period i.e., between 2024-2036.

North America industry is expected to hold largest revenue share by 2036, attributed to factors such as high healthcare expenditure, and amplified intake of human growth hormone therapies in the region in order to cure different syndromes such as Turner syndrome.

The major players in the market are Merck KGaA, Teva Pharmaceuticals Industries Ltd., Ipsen Pharma Biotech SAS, Novartis AG, Pfizer, Inc., F. Hoffmann-La Roche Ltd, Ferring B.V., Novo Nordisk A/S, Eli Lilly and Company, AnkeBio Co., Ltd, and others.

Inquiry Before Buying Request Free Sample